Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | MGLL | Q99685 | 1/20 | 0.56 |
| ▸ | TSPO | P30536 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117205 | 0.88 | LMNA (0.57) | LMNAALDH1A1TSHRMGLLNPC1 | |
| SCHEMBL1195514 | 0.86 | LMNA (0.78) | LMNAALDH1A1TSHRMAPK1MGLL | |
| SCHEMBL3836681 | 0.82 | LMNA (0.72) | LMNAALDH1A1TSHRMAPK1MGLL | |
| SCHEMBL9547626 | 0.82 | LMNA (0.92) | LMNAALDH1A1TSHRMAPK1MGLL | |
| SCHEMBL968384 | 0.82 | LMNA (0.72) | LMNAALDH1A1TSHRMAPK1MGLL | |
| SCHEMBL25138742 | 0.81 | HDAC1 (0.71) | LMNAALDH1A1TSHRMAPK1HDAC1 | |
| SCHEMBL1004019 | 0.81 | HDAC1 (0.71) | LMNAALDH1A1TSHRMAPK1MGLL | |
| SCHEMBL967320 | 0.81 | LMNA (0.70) | LMNAALDH1A1TSHRMAPK1MGLL | |
| SCHEMBL137359 | 0.81 | LMNA (0.70) | LMNAALDH1A1TSHRMAPK1MGLL | |
| SCHEMBL9029799 | 0.81 | LMNA (0.70) | LMNAALDH1A1TSHRMAPK1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | claimed |
| EP-1501797-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-08 | — | — | US | claimed |
| WO-2003091214-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | claimed |
| EP-1501797-B1 | 3-(SUBSTITUTED AMINO)-1H-INDOLE-2-CARBOXYLIC ACID ESTER AND 3-(SUBSTITUTED AMINO)-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID ESTER DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | disclosed |
| EP-1501797-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003091214-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | IL4, STAT4, BCL6 | LMNA 4805/4885ALDH1A1 1578/4885TSHR 1105/4885 |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | IL4, STAT4, STAT6 | LMNA 4793/4885ALDH1A1 1900/4885TSHR 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.